MHRA inspections of GMP sites, deficiency grades and preparation
MHRA inspections check GMP compliance at medicine manufacturers. How sites are chosen, what inspectors examine, how findings are graded and what follows.
MHRA inspections of GMP manufacturing sites
MHRA inspections of medicine manufacturers check whether a site complies with good manufacturing practice (GMP). Inspectors interview staff, review documents and visit relevant facilities. They grade findings as critical, major or other. The company must propose corrective actions and completion dates (MHRA GMP and GDP guidance).
This guide covers GMP inspections of manufacturing sites only, not good distribution practice or the MHRA's other inspection programmes.
When and why the MHRA inspects a site
A manufacturer is inspected when it applies for a manufacturing licence, and then periodically, based on risk. Overseas manufacturing sites can be inspected too. Sites with the highest GMP risk ratings are prioritised. That rating is based on the compliance report, internal information about previous inspection history, and organisational changes (MHRA guidance). There is no single fixed interval, such as every two or three years, that applies to every site.
The guidance describes three types of GMP inspection:
| Type | What triggers it | Notice |
|---|---|---|
| Routine | The site's risk-based inspection schedule | Told in advance, though the short-notice programme may give little or no notification |
| Product-related | Supporting assessment of a UK marketing authorisation application | Told in advance |
| Triggered | A suspected breach, for example a whistleblower report or a referral from another MHRA department or another regulator | Little or no notice possible |
Source: MHRA GMP and GDP guidance.
Before a routine or product-related inspection, the company has to complete a GMP compliance report. A triggered inspection notified only at short notice is the exception (MHRA guidance).
Oversight is not always an on-site visit. An MHRA Inspectorate blog post from 16 May 2025 describes desk-based GMP Compliance Assessments, and says risk-based oversight continues through on-site inspections or distant assessments. Do not use the certificate expiry date alone to predict the next inspection.
What an MHRA inspector looks for
The GMP inspection process gathers evidence from staff, records and the site itself. Inspectors interview personnel, examine documents and visit the facilities relevant to the licence. They can ask for samples or extra documentation. If they suspect serious non-compliance, they can change the focus of the inspection (MHRA guidance).
The inspector tests whether what staff say, what the records show and what is happening on the floor all agree. Preparation is about showing the site is in control day to day. No official checklist guarantees a clean outcome.
At the closing meeting, the inspector gives feedback, discusses the deficiencies and agrees timelines for corrective action (MHRA guidance).
How MHRA grades critical, major and other deficiencies
Each finding gets one of three grades. The table paraphrases the MHRA's published summaries for manufacturing (MHRA guidance).
| Grade | What it means |
|---|---|
| Critical | Has produced, or significantly risks producing, a product that is harmful to humans or veterinary patients, or that could result in a harmful residue in a food-producing animal |
| Major | Not critical, but it has produced or may produce a product that does not comply with its marketing authorisation, or it indicates a major deviation from GMP or the manufacturing licence, or a failure to carry out satisfactory batch release |
| Other | A departure from GMP that cannot be classified as critical or major, or where there is not enough information to classify it as critical or major |
An "other" deficiency is still a GMP departure that needs corrective action. Several "other" deficiencies may not be major alone, but together they may represent a major deficiency. The MHRA says that combination should be explained and reported as such (MHRA grading guidance).
What happens after the inspection
After the visit, the MHRA sends a post-inspection letter that confirms the deficiencies. The company must reply by email with proposed corrective actions and completion dates. If the inspector accepts the response, the MHRA issues the GMP certificate with the GMP inspection report. An unacceptable response may lead to compliance escalation if further requests for information are unsatisfactory (MHRA guidance).
If the inspector finds critical deficiencies, or agreed action plans from a previous inspection that have not been resolved, they will contact the Inspection Action Group (IAG). The IAG can refuse or suspend a licence, increase the number of inspection visits or ask the company to a meeting. A major deficiency does not automatically suspend a licence (MHRA compliance guidance).
Follow the response deadline stated in your own post-inspection letter.
An MHRA Inspectorate blog post from 29 June 2026 says a response should be accurate and verifiable, technically reviewed by experienced people, signed off by someone with authority and accountability, and backed by evidence. Inaccurate, incomplete or overly verbose responses may be returned or rejected. Poor corrective and preventive action (CAPA) may raise the site's inspection priority or lead to an IAG referral.
What MHRA GMP inspection findings data shows
The MHRA publishes GMP inspection deficiency statistics on GOV.UK. The page was published on 15 October 2014 and last updated on 15 October 2020, when the 2019 data was added. The newest year it lists is 2019. Downloads include a 2019 summary and spreadsheets for 2018 and 2019, plus older GMP summaries. One listed file is 2016 GDP data, so do not treat every attachment as current GMP findings (MHRA GMP inspection deficiencies).
Treat this as historical material. The 2019 data describes inspections from years ago, and the EU GMP text it refers to may have changed since, so it is not a ranking of what inspectors focus on today. Old clause references are also a poor checklist, particularly for sterile manufacturing.
Read with those limits, the 2019 material points to two recurring themes in the EU GMP guide, EudraLex Volume 4. Chapter 1 is the Pharmaceutical Quality System. Chapter 4 is Documentation (European Commission).
- Pharmaceutical quality system findings, including root-cause investigation and CAPA. Chapter 1, which those findings point to, calls for appropriate root-cause analysis, a justified conclusion where human error is named as the cause, and monitoring of whether CAPA works.
- Documentation findings, including records made at the time. Chapter 4 calls for records made at the time each action is taken.
Sources: MHRA GMP inspection deficiencies and EudraLex Volume 4.
If you use the spreadsheets, check the counting method before comparing tables. Establish whether each table counts cited GMP references, deficiencies, sites or inspections, and which grades it includes.
How to prepare for an on-site GMP inspection
Use these practical checks to prepare evidence for inspection. They draw on the MHRA inspection process and the historical themes above, not an official exhaustive checklist.
- Review open and recent investigations. Check that each one reaches a supported root cause, that any "human error" conclusion is justified, and that CAPA effectiveness is checked and recorded.
- Sample batch records and logbooks for contemporaneous entries. Records made after the event are a documentation risk.
- Make sure staff can explain their own procedures, and that their account matches the written procedure and the records.
- Keep evidence that past corrective actions were completed, especially actions promised to the MHRA after an earlier inspection.
- Prepare to supply documents and samples during the visit. Inspectors can ask for both.
- After the inspection, answer each deficiency in the post-inspection letter with a specific action, a completion date and supporting evidence, within the timeline the letter gives. Have the response technically reviewed and authorised before you send it.
For a cited answer to what MHRA inspectors look for and how deficiencies are graded, with links to the stored source documents, see this RegAffairs AI answer.